Natural killer cells of the immune system are actually designed to hunt cancer cells. The problem: solid tumors shield themselves through a network of immunosuppressive signaling molecules and neutralize these cells. Researchers at the Rosalind and Morris Goodman Cancer Institute at McGill University have now found a way to break this blockade using small molecules.
Why the immune system often cannot do enough against cancer
Natural killer cells (NK cells) patrol the bloodstream and recognize abnormal cells by missing or altered surface features. Unlike T cells, they don't need prior sensitization. In healthy tissue, they kill efficiently. But in tumor tissue, cancer cells release signaling molecules that essentially put NK cells to sleep. Particularly effective is transforming growth factor beta 1 (TGFβ-1), a molecule also known for wound healing that systematically suppresses the immune system in the tumor environment.
Several pharmaceutical companies have attempted to directly block TGFβ-1. Results have been disappointing so far, in part because the molecule has many physiological functions and blocking it triggers side effects on other organs.
The new approach: Shutting down two proteins in killer cells
The McGill team, whose results appeared in EMBO Reports in April 2026, pursued a different strategy. Rather than blocking TGFβ-1 itself, the researchers inhibited two proteins in the NK cells themselves: PTPN1 and PTPN2. These protein tyrosine phosphatases are intracellular signaling brakes that downregulate NK cell activity. When inhibited, NK cells become more responsive to activation signals and produce more of the cytokine interleukin-2, boosting their fighting power.
Crucially: the team used reversible small-molecule inhibitors, not permanent genetic changes. NK cells can return to their baseline state after treatment. This is a significant practical advantage over approaches that permanently alter cellular genetic information.
Four cancer types, one mechanism
The activated NK cells were tested against four different cancers: acute myeloid leukemia, glioblastoma (an aggressive brain tumor), renal cell carcinoma, and triple-negative breast cancer, a particularly difficult-to-treat subtype. In all four models, treated NK cells showed significantly elevated killing rates. The team reports that the activated NK cells also resisted TGFβ-1, the standard immunosuppressor that normally completely disables them.
Triple-negative breast cancer deserves particular attention: this subtype does not respond to hormone therapies and is only limitedly accessible to checkpoint inhibitors. New therapeutic approaches are urgently needed here.
In comparison: What other immunotherapies achieve
NK cells as a therapy tool have a structural advantage over other forms of immunotherapy: they can be obtained from donor blood and produced in large quantities without needing to be tailored to a specific patient. This fundamentally distinguishes them from CAR-T cells, which received their first approvals in 2017. For CAR-T therapy, a patient's own cells must be removed, genetically reprogrammed, and reinfused. The process takes weeks and costs hundreds of thousands of dollars, severely limiting accessibility.
Checkpoint inhibitors, used clinically since 2014 and blocking PD-1 or PD-L1, achieve impressive long-term remissions in some cancers. However, their principle of action assumes that T cells are functional and numerous enough within the tumor. Glioblastomas and renal cell carcinomas are known for often preventing this. Here, the NK cell route could offer a complement or alternative.
The path to the clinic: Acute leukemia comes first
Acute myeloid leukemia (AML) is the cancer type the McGill team has designated for future clinical trials. This makes therapeutic sense: in AML, cancer cells circulate in the blood and are easily accessible to infused NK cells. Solid tumors like glioblastoma present a higher mechanistic hurdle because NK cells must first penetrate into the tumor tissue.
The typical timeline from preclinical data to market approval in oncology is ten to fifteen years. If planned Phase I studies start in the next two to three years and provide positive safety data, patients outside of studies could have access as early as the first half of the 2030s. For cancer patients diagnosed with AML today, this is not quick help. But it is the kind of fundamental mechanism research on which all future NK cell therapies will be built.
